Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 5/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
| ▸ | CLK2 | P49760 | 3/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.36 |
| ▸ | CLK1 | P49759 | 2/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869578 | 0.94 | BACE1 (0.41) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869726 | 0.92 | EGFR (0.38) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869695 | 0.92 | EGFR (0.38) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869796 | 0.90 | GRIA1 (0.42) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869426 | 0.89 | GRIA1 (0.42) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869822 | 0.88 | GRIA1 (0.41) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869445 | 0.84 | GRIA1 (0.43) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869642 | 0.84 | EGFR (0.35) | EGFRBACE1ROCK1ROCK2CHRNA7 | |
| SCHEMBL30869734 | 0.83 | EGFR (0.55) | EGFRROCK1ROCK2GSK3BCDK5 | |
| SCHEMBL30869455 | 0.83 | GRIA1 (0.40) | EGFRBACE1ROCK1ROCK2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | EGFR 1355/4885BACE1 1711/4885ROCK1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.